STOCK TITAN
  1. Home
  2. News
  3. CSLLY

CSL LTD SP/ADR - CSLLY STOCK NEWS

Welcome to our dedicated page for CSL SP/ADR news (Ticker: CSLLY), a resource for investors and traders seeking the latest updates and insights on CSL SP/ADR stock.

CSL LTD SP/ADR (CSL) is a global biotechnology company known for its innovative therapies in iron deficiency and nephrology. Headquartered in St. Gallen, Switzerland, CSL Vifor, a division of CSL, focuses on strategic global partnerships, innovative pharmaceuticals, and precision healthcare solutions. Their portfolio includes Ferinject, an IV iron therapy with marketing authorization in 87 countries as of 2024, addressing iron deficiency anemia and heart failure in adults and pediatric patients. With a workforce of 32,000, CSL delivers life-saving products worldwide, striving to improve patients' quality of life.

News

CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
-
News

Seqirus Presents New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
clinical trial
-
News

Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
News

Seqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious Diseases

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
News

Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
News

New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
News

Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
fda approval
-
News

U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News

Seqirus Publishes New Real-World Evidence (RWE) on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Vaccines

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
News

Seqirus Real World Evidence Published in Vaccine Highlights Value of Cell-Based Quadrivalent Influenza Vaccine in Preventing Influenza Related Hospitalizations in the U.S. 2017/18 Season

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none

FAQ

What is the current stock price of CSL SP/ADR (CSLLY)?

The current stock price of CSL SP/ADR (CSLLY) is $100.3 as of September 6, 2024.

What is the market cap of CSL SP/ADR (CSLLY)?

The market cap of CSL SP/ADR (CSLLY) is approximately 101.0B.

What is CSL LTD SP/ADR known for?

CSL is known for its innovative therapies in iron deficiency and nephrology, focusing on precision healthcare solutions.

Where is CSL LTD SP/ADR headquartered?

CSL LTD SP/ADR is headquartered in St. Gallen, Switzerland.

What is CSL Vifor's specialization?

CSL Vifor focuses on strategic global partnerships, innovative pharmaceuticals, and precision healthcare solutions.

What is Ferinject?

Ferinject is an IV iron therapy marketed in 87 countries, addressing iron deficiency anemia and heart failure in adults and pediatric patients.

How many countries does CSL deliver its products to?

CSL delivers life-saving therapies to people in more than 100 countries worldwide.

Stock CSLLY logo
CSL LTD SP/ADR

OTC:CSLLY

CSLLY Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CSLLY Stock Data

101.03B
482.99M
0.02%
Biotechnology
Healthcare
Link
United States of America
Melbourne